Pfizer Management
Management criteria checks 3/4
Pfizer's CEO is Albert Bourla, appointed in Jan 2019, has a tenure of 7.67 years. total yearly compensation is $27.59M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth $12.04M. The average tenure of the management team and the board of directors is 6.4 years and 7.9 years respectively.
Key information
Albert Bourla
Chief executive officer
US$27.6m
Total compensation
| CEO salary percentage | 6.53% |
| CEO tenure | 7.7yrs |
| CEO ownership | 0.008% |
| Management average tenure | 6.4yrs |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 28 2026 | n/a | n/a | US$4b |
| Mar 29 2026 | n/a | n/a | US$7b |
| Dec 31 2025 | US$28m | US$2m | US$8b |
| Sep 28 2025 | n/a | n/a | US$10b |
| Jun 29 2025 | n/a | n/a | US$11b |
| Mar 30 2025 | n/a | n/a | US$8b |
| Dec 31 2024 | US$25m | US$2m | US$8b |
| Sep 29 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | -US$3b |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$22m | US$2m | US$2b |
| Oct 01 2023 | n/a | n/a | US$10b |
| Jul 02 2023 | n/a | n/a | US$21b |
| Apr 02 2023 | n/a | n/a | US$29b |
| Dec 31 2022 | US$33m | US$2m | US$31b |
| Oct 02 2022 | n/a | n/a | US$30b |
| Jul 03 2022 | n/a | n/a | US$29b |
| Apr 03 2022 | n/a | n/a | US$25b |
| Dec 31 2021 | US$24m | US$2m | US$22b |
| Oct 03 2021 | n/a | n/a | US$19b |
| Jul 04 2021 | n/a | n/a | US$12b |
| Apr 04 2021 | n/a | n/a | US$9b |
| Dec 31 2020 | US$21m | US$2m | US$7b |
| Sep 27 2020 | n/a | n/a | US$212m |
| Jun 28 2020 | n/a | n/a | US$7b |
| Mar 29 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$18m | US$2m | US$11b |
Compensation vs Market: Albert's total compensation ($USD27.59M) is above average for companies of similar size in the AR market ($USD5.24M).
Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.
CEO
Albert Bourla (64 yo)
Dr. Albert Bourla, DVM, Ph.D. serves as Chairman & CEO at Pfizer Venture Investments LLC. He serves as CEO from January 2019. He serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 7.7yrs | US$27.59m | 0.0076% $ 12.0m | |
| Chief Scientific Officer and President of Research & Development | 1.7yrs | US$10.01m | 0.0028% $ 4.5m | |
| Executive VP & Chief Legal Officer | 12.8yrs | US$9.11m | 0.0029% $ 4.6m | |
| Executive VP & Chief U.S. Commercial Officer | 5.1yrs | US$9.43m | 0.00052% $ 819.8k | |
| Interim CFO & Executive VP | less than a year | no data | 0.0026% $ 4.1m | |
| Senior VP | 6.5yrs | no data | 0.00050% $ 788.3k | |
| Executive VP & Chief Information Officer | less than a year | no data | 0.00083% $ 1.3m | |
| Chief Investor Relations Officer | no data | no data | no data | |
| Chief People Experience Officer & Executive VP | 6.3yrs | no data | 0.00074% $ 1.2m | |
| Senior VP and Chief Scientific Officer of Inflammation & Immunology | 10.3yrs | no data | no data | |
| Chief Scientific Officer of Oncology | 7.2yrs | no data | no data | |
| Senior Vice President of Global Gene Therapy Business | no data | no data | no data |
Experienced Management: PFED's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.7yrs | US$27.59m | 0.0076% $ 12.0m | |
| Independent Director | 6.4yrs | US$380.52k | 0.000060% $ 94.6k | |
| Lead Independent Director | 13yrs | US$410.00k | no data | |
| Independent Director | 9.6yrs | US$360.00k | 0.0013% $ 2.0m | |
| Independent Director | 19yrs | US$410.00k | 0.00018% $ 283.8k | |
| Independent Director | 12.3yrs | US$390.00k | 0.000060% $ 94.6k | |
| Independent Director | 1.9yrs | US$360.00k | 0.00066% $ 1.0m | |
| Independent Director | 8.5yrs | US$380.00k | no data | |
| Independent Director | 6.6yrs | US$380.00k | no data | |
| Independent Director | 2.3yrs | US$380.00k | 0.00018% $ 283.8k | |
| Independent Director | 7.3yrs | US$393.50k | 0.00018% $ 283.8k | |
| Independent Director | 11.3yrs | US$400.37k | no data |
Experienced Board: PFED's board of directors are considered experienced (7.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 19:11 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/28 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Inc. is covered by 45 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| "Emily Field | Barclays |